logo
  

D.R. Horton's Longtime CEO Donald Tomnitz Retiring

Homebuilder D.R. Horton, Inc. (DHI) said Tuesday that its Vice Chairman, President and Chief Executive Officer, Donald Tomnitz, will retire effective October 1.

Tomnitz is also retiring from the company's Board of Directors. He will remain in a consulting role with the company for three years.

The company said it has appointed David Auld, currently Executive Vice President and Chief Operating Officer, as President and Chief Executive Officer.

Auld joined D.R. Horton in 1988 as Division President of the company's Orlando Division. In 2005, he was promoted to Region President overseeing all D.R. Horton homebuilding divisions in Florida, North and South Carolina, Georgia and Alabama. In November 2013, he was promoted to Executive Vice President and Chief Operating Officer.

Tomnitz's retirement culminates an outstanding career of 31 years at D.R. Horton. He has been the company's President and Chief Executive Officer since November 1998.

Tomnitz said, "After over three decades with the company and 15 years as CEO, it's time for a new generation of leadership at D.R. Horton, and the Company is well-positioned for continued success. I am happy for David in his new role as CEO, and I look forward to continuing to work with him, D.R., and the rest of the management team in a consulting role."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
RELATED NEWS
Follow RTT